SARS-CoV-2 Polypeptide Vaccine Design
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vaccine candidates for SARS-CoV-2 face challenges due to the virus's variability, requiring persistent efforts for development, and existing vaccines may have limitations in global distribution due to production, storage, and handling costs.
Innovation Solution
An isolated polypeptide with specific amino acid sequences or fragments thereof, designed to elicit an immune response by forming complexes with major histocompatibility complex molecules, is used in immunogenic compositions to generate adaptive immune responses against SARS-CoV-2.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional vaccines are developed and distributed globally, then immune protection against SARS-CoV-2 is achieved, but production, storage, and handling costs increase
Solution Approach 1:
The patent extracts only the essential immunogenic components (specific amino acid sequences from SARS-CoV-2 proteins) needed to elicit an immune response, removing unnecessary viral materials. This extraction approach creates a simplified vaccine composition that maintains immunogenicity while reducing production complexity and cost.
Solution Approach 2:
The patent changes the molecular parameters of the vaccine by using defined amino acid sequences (10-50 residues) instead of whole viral proteins. This parameter change enables more efficient production through recombinant expression systems and reduces the need for complex purification processes, thereby lowering manufacturing costs while maintaining immune protection.
2Adaptability or versatility
If peptide-based vaccines are designed to cover multiple variants, then broad population coverage is achieved, but vaccine complexity increases
Solution Approach 1:
The patent designs peptide sequences that serve multiple functions: they can bind to MHC molecules, elicit T-cell responses, and provide protection against multiple SARS-CoV-2 variants. By selecting conserved regions that are universally recognized across variants, a single vaccine composition achieves broad population coverage without requiring multiple variant-specific formulations.
Solution Approach 2:
The patent segments the SARS-CoV-2 proteome into specific immunogenic peptide regions (10-50 amino acid residues) that can be independently expressed and tested. This segmentation allows for modular vaccine design where individual peptide sequences can be optimized for specific HLA alleles while maintaining overall vaccine simplicity through focused target selection.
3Productivity
If recombinant vaccine production is implemented, then manufacturing efficiency is improved, but production infrastructure requirements increase
Solution Approach 1:
The patent employs transient expression systems and disposable cell culture formats for recombinant peptide production. Rather than requiring permanent, complex bioreactor infrastructure, the approach uses simplified, single-use production methods that can be scaled more easily and reduce the need for expensive, specialized manufacturing facilities while maintaining high productivity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The polypeptide-based immunogenic compositions effectively induce both humoral and cell-mediated immune responses, providing broad population coverage and stability against SARS-CoV-2 variants, with potential for cost-effective production and distribution.
Implementation Method 1
designed to elicit an immune response by forming complexes with major histocompatibility complex molecules
Data Source
AI summary
The present invention relates to an isolated polypeptide that finds utility in generating an immune response against a virus in a subject. Also disclosed are immunogenic compositions comprising the isolated polypeptide, generating an immune response against a virus in a subject, and preventing or treating a viral infection in a subject, in particular a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.